Literature DB >> 953993

Distribution and excretion of (3H)vincristine in the rat and the dog.

M C Castle, D A Margileth, V T Oliverio.   

Abstract

The distribution and excretion of tritiated vincristine were studies in the rat and the dog. Biphasic curves for the disappearance of the drug from blood were found in both species, with an initial half-life of approximately 15 min and a secondary half-life of approximately 75 min. Tissue levels were high in 1 hr in the rat and declined rapidly, except in the brain where very low levels of drug were found at all times. The bile was found to be the major route of excretion. The peak rate of excretion in bile was found to occur earlier in the rat (10 min) than in the dog (60 min). Rats given a higher dose of vincristine (1.0 mg/kg) excreted a larger percentage of the dose in the bile than rats given a lower dose (0.1 mg/kg). In rats given a low dose of vincristine (0.1 mg/kg), more than 85% of the drug was excreted in the feces and the urine over 72 hr. Less than 10% of the total radioactivity in the bile and urine was metabolites whereas, in the plasma, metabolites accounted for 40% of the total radioactivity.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 953993

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  20 in total

Review 1.  Antineoplastic drugs: clinical pharmacology and therapeutic use.

Authors:  R A Bender; L A Zwelling; J H Doroshow; G Y Locker; K R Hande; D S Murinson; M Cohen; C E Myers; B A Chabner
Journal:  Drugs       Date:  1978-07       Impact factor: 9.546

2.  A sensitive radioimmunoassay for vincristine and vinblastine.

Authors:  V S Sethi; S S Burton; D V Jackson
Journal:  Cancer Chemother Pharmacol       Date:  1980       Impact factor: 3.333

3.  Diet-induced obesity alters vincristine pharmacokinetics in blood and tissues of mice.

Authors:  James W Behan; Vassilios I Avramis; Jason P Yun; Stan G Louie; Steven D Mittelman
Journal:  Pharmacol Res       Date:  2010-01-18       Impact factor: 7.658

4.  Tissue disposition, excretion and metabolism of vinblastine in mice as determined by high-performance liquid chromatography.

Authors:  O van Tellingen; J H Beijnen; W J Nooijen; A Bult
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

5.  The pharmacokinetics and metabolism of N-desmethyl-N-formyl-leurosine (F-leurosine) in the rat.

Authors:  S Ronai-Lukacs; L Vereczkey
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1982 Jan-Mar       Impact factor: 2.441

6.  Brain uptake and anticancer activities of vincristine and vinblastine are restricted by their low cerebrovascular permeability and binding to plasma constituents in rat.

Authors:  N H Greig; T T Soncrant; H U Shetty; S Momma; Q R Smith; S I Rapoport
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

7.  Retardation of rat sciatic nerve regeneration after local application of minute doses of vincristine.

Authors:  G S Ruigt; M H den Brok
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

Review 8.  Lipid-Based Drug Delivery Systems in Cancer Therapy: What Is Available and What Is Yet to Come.

Authors:  Phatsapong Yingchoncharoen; Danuta S Kalinowski; Des R Richardson
Journal:  Pharmacol Rev       Date:  2016-07       Impact factor: 25.468

9.  Pharmacokinetics of vincristine, vinblastine, and vindesine in rhesus monkeys.

Authors:  V S Sethi; P Surratt; C L Spurr
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

10.  Nociceptor hyper-responsiveness during vincristine-induced painful peripheral neuropathy in the rat.

Authors:  K D Tanner; D B Reichling; J D Levine
Journal:  J Neurosci       Date:  1998-08-15       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.